CompletedNot Applicable

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

United States143 participantsStarted 2022-03-04

Plain-language summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Who can participate

Age range30 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female * 30-65 years of age * Interested in glabellar injections to reduce rhytids and facial strain * Participants must sign the informed consent form Exclusion Criteria: * Females under 30 or above 65 years of age * Males * Those who have received glabellar injections for rhytids \<12 months * Underwent cosmetic surgical procedure above the malar region * Those with a condition that affects facial expression, such as prior stroke

What they're measuring

the Change in Dynamic Strain in the Glabella Area After Injection Over Time

Timeframe: day 3, day 30, day 90, day 180

Trial details

NCT IDNCT05167864

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-30

Results submitted2024-05-13

View on ClinicalTrials.gov More Cosmetic Techniques trials